AU2001253601A1 - 5-substituted tetralones as inhibitors of ras farnesyl transferase - Google Patents

5-substituted tetralones as inhibitors of ras farnesyl transferase

Info

Publication number
AU2001253601A1
AU2001253601A1 AU2001253601A AU5360101A AU2001253601A1 AU 2001253601 A1 AU2001253601 A1 AU 2001253601A1 AU 2001253601 A AU2001253601 A AU 2001253601A AU 5360101 A AU5360101 A AU 5360101A AU 2001253601 A1 AU2001253601 A1 AU 2001253601A1
Authority
AU
Australia
Prior art keywords
inhibitors
farnesyl transferase
ras farnesyl
substituted tetralones
tetralones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253601A
Inventor
William Alexander Denny
Richard H. Hutchings
Douglas S. Johnson
James Stanley Kaltenbronn
Ho Huat Lee
Daniele Marie Leonard
Jared Bruce John Milbank
Joseph Thomas Repine
Gordon William Rewcastle
Andrew David White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001253601A1 publication Critical patent/AU2001253601A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001253601A 2000-04-17 2001-04-16 5-substituted tetralones as inhibitors of ras farnesyl transferase Abandoned AU2001253601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19748500P 2000-04-17 2000-04-17
US60197485 2000-04-17
PCT/US2001/012490 WO2001079180A2 (en) 2000-04-17 2001-04-16 5-substituted tetralones as inhibitors of ras farnesyl transferase

Publications (1)

Publication Number Publication Date
AU2001253601A1 true AU2001253601A1 (en) 2001-10-30

Family

ID=22729601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253601A Abandoned AU2001253601A1 (en) 2000-04-17 2001-04-16 5-substituted tetralones as inhibitors of ras farnesyl transferase

Country Status (8)

Country Link
US (1) US6943183B2 (en)
EP (1) EP1276725A2 (en)
JP (1) JP2003531143A (en)
AU (1) AU2001253601A1 (en)
BR (1) BR0110142A (en)
CA (1) CA2405696A1 (en)
MX (1) MXPA02010098A (en)
WO (1) WO2001079180A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001926B2 (en) 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
WO2003072547A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US11479766B2 (en) * 2013-12-05 2022-10-25 New England Biolabs, Inc. Methods for labeling a population of RNA molecules
CN108794308B (en) * 2017-04-27 2021-07-20 北京大学深圳研究生院 1,2,3, 4-tetrahydronaphthalene compound and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase

Also Published As

Publication number Publication date
WO2001079180A3 (en) 2002-05-23
WO2001079180A2 (en) 2001-10-25
BR0110142A (en) 2003-01-21
US6943183B2 (en) 2005-09-13
JP2003531143A (en) 2003-10-21
US20040044057A1 (en) 2004-03-04
CA2405696A1 (en) 2001-10-25
EP1276725A2 (en) 2003-01-22
MXPA02010098A (en) 2003-02-12

Similar Documents

Publication Publication Date Title
AU2001243158A1 (en) Inhibitors of prenyl-protein transferase
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2002211427A1 (en) Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001238217A1 (en) Inhibitors of prenyl-protein transferase
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001247197A1 (en) Inhibitors of prenyl-protein transferase
AU2477400A (en) Inhibitors of prenyl-protein transferase
AU2002236813A1 (en) Treatment of malaria with farnesyl protein transferase inhibitors
AU7354900A (en) Inhibitors of prenyl-protein transferase
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
AU2001227757A1 (en) Inhibitors of prenyl-protein transferase
AU2001238424A1 (en) Inhibitors of prenyl-protein transferase
AU2274101A (en) Inhibitors of prenyl-protein transferase
AU2001253601A1 (en) 5-substituted tetralones as inhibitors of ras farnesyl transferase
AU2001230864A1 (en) Inhibitors of prenyl-protein transferase
DK1339695T3 (en) Farnesyl transferase inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2001229320A1 (en) Inhibitors of prenyl-protein transferase
AU6678398A (en) Inhibitors of isoprenyl transferase
AU2002254375A1 (en) Inhibitors of prenyl-protein transferase
AU2001227756A1 (en) Inhibitors of prenyl-protein transferase
EE200200206A (en) Farnesyl transferase inhibitors
AU2001251445A1 (en) Inhibitors of prenyl-protein transferase